摘要
肝纤维化是一种世界范围内高发病率与高死亡率的疾病,与癌症、艾滋病并称"世纪三大顽疾"。肝纤维化的具体发病机制尚不明确,主要表现为肝组织损伤和修复异常、肝星状细胞增殖活化、细胞外基质累积。目前尚无有效治疗肝纤维化的方法,也没有相关药物获批上市。然而近年来,越来越多的肝纤维化治疗药物逐步进入临床研究阶段。对肝纤维化发病机制及其治疗药物的研究进展进行综述,旨在为该疾病的深入研究及相关新药研发提供参考。
Liver fibrosis,a global threat with high morbidity and mortality,is one of the three intractable diseases of the 20 th century,together with cancer and AIDS.Pathological mechanism of liver fibrosis still remains unclear,with its main manifestations of liver tissue damage and abnormal repair,proliferation and activation of hepatic stellate cells(HSCs),as well as accumulation of extracellular matrix(ECM).There is no effective therapy for liver fibrosis,with no approved drugs.However,in recent years,more and more drugs for the treatment of liver fibrosis have been gradually put under clinical trials.This paper reviews the pathological mechanisms of hepatic fibrosis and the research progress of related therapeutic drugs,so as to provide reference for further research on liver fibrosis and R&D of its related new drugs.
作者
司晶
唐露
李臣诚
徐寒梅
SI Jing;TANG Lu;LI Chencheng;XU Hanmei(China Pharmaceutical University,Nanjing 211198,China;Nanjing Anji Biotechnology Co.,Ltd.,Nanjing 210046,China)
出处
《药学进展》
CAS
2021年第3期205-211,共7页
Progress in Pharmaceutical Sciences
基金
南京市国际产业技术研发合作项目资助(No.201818020)。
关键词
肝纤维化
肝星状细胞
炎症
发病机制
治疗药物
liver fibrosis
hepatic stellate cell
inflammation
pathogenesis
therapeutic drug
